171 related articles for article (PubMed ID: 29257907)
1. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.
Rezahosseini O; Hanaei S; Hamadani M; Keshavarz-Fathi M; Rezaei N
Int Rev Immunol; 2018 May; 37(3):165-173. PubMed ID: 29257907
[TBL] [Abstract][Full Text] [Related]
2. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Herrera AF
Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Chu Y; Hanley PJ; Cairo MS
Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
6. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
7. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
9. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
Foster WR; Bischin A; Dorer R; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
[TBL] [Abstract][Full Text] [Related]
10. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
Maloney DG; Press OW
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Bounaix L; Bendouda M; Bay JO; Lemal R
Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P
Haematologica; 2020 Apr; 105(4):1032-1041. PubMed ID: 31296574
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
Jourdan E; Richard B
Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
[TBL] [Abstract][Full Text] [Related]
16. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
[TBL] [Abstract][Full Text] [Related]
17. A review of monoclonal antibody therapies in lymphoma.
Teo EC; Chew Y; Phipps C
Crit Rev Oncol Hematol; 2016 Jan; 97():72-84. PubMed ID: 26318093
[TBL] [Abstract][Full Text] [Related]
18. [Auto-immune manifestations in Non-Hodgkin's lymphoma].
Jardin F; Lévesque H; Tilly H
Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for HIV-associated non-Hodgkin's lymphoma.
Newsom-Davis T; Ahamed E; Bower M
Expert Opin Biol Ther; 2009 Oct; 9(10):1313-24. PubMed ID: 19645631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]